Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 7/20 | 0.38 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | GJB2 | P29033 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13806499 | 1.00 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL15296514 | 1.00 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL14900306 | 1.00 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL13772551 | 0.91 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL17794462 | 0.91 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL17794461 | 0.91 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL15267655 | 0.91 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL13772552 | 0.91 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL15267653 | 0.91 | TNF (0.40) | TNFMAPK1LGALS8CD209SLC2A1 | |
| SCHEMBL15296532 | 0.90 | TNF (0.35) | TNFMAPK1LGALS8GJB2LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857411-B1 | METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2017-12-06 | — | — | EP | disclosed |
| EP-2809678-B1 | AN EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9243018-B2 | Synthetic heparin pentasaccharides | DR. REDDY'S LABORATORIES, SA (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150284419-A1 | METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2015-10-08 | — | — | US | disclosed |
| EP-2857411-A1 | METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2015-04-08 | — | — | EP | disclosed |
| US-8987430-B2 | Efficient and scalable process for the manufacture of fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150005485-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2015-01-01 | — | — | US | disclosed |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013115817-A1 | AN EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8420790-B2 | Efficient and scalable process for the manufacture of Fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8404833-B2 | Synthetic heparin disaccharides | ALCHEMIA LIMITED (AU) | 2013-03-26 | — | — | US | disclosed |
| US-20120220759-A1 | SYNTHETIC HEPARIN DISACCHARIDES | ALCHEMIA LIMITED (AU) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284419-A1 | METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF | HABP2, HPSE, PLG | TNF 2015/4885MAPK1 3846/4885LGALS8 2747/4885 |
| US-20120220759-A1 | SYNTHETIC HEPARIN DISACCHARIDES | HPSE, DDOST, STT3A | TNF 1459/4885MAPK1 2919/4885LGALS8 609/4885 |
| US-20150005485-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | TNF 1297/4885MAPK1 3480/4885LGALS8 719/4885 |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | TNF 2145/4885MAPK1 3255/4885LGALS8 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.